# Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects

> **NCT02742766** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 104 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** GSK3008356
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02742766
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-14
- **Primary completion:** 2017-06-16
- **Final completion:** 2017-06-16
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2019-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02742766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02742766, "Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02742766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*